Contribute Try STAT+ Today

WASHINGTON — The Department of Health and Human Services is moving forward with a policy that could require drug companies to put the price of their medicine in advertisements.

The White House Office of Management and Budget received a draft regulation from HHS this week titled “Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency.” An HHS spokesperson declined to comment on what the regulation would do, but lobbyists told STAT that it relates to the policy of requiring drug price information in ads.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.